Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma STI-1492

What's the purpose of this trial?

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments.
  • Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
  • Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma
  • Pulse oximetry ≥ 92% on room air
  • Have a life expectancy ≥ 12 weeks
  • Be willing and able to comply with the study schedule and all study requirements
  • Willing to follow contraception guidelines

Exclusion Criteria:

  • Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose
  • Treatment with any cellular therapy within 8 weeks prior to start of study dose
  • Have any unresolved toxicity ≥ Grade 2 from previous anticancer therapies
  • A history of brain metastasis or spinal cord compression
  • Has an ECOG performance status (PS) ≥ 3
  • Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant
  • Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM
  • Has any clinically significant elevated baseline lab results for serum creatinine, AST or β2 microglobulin
  • Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
  • Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
  • Is currently pregnant or breast feeding or planning on either during the study.
  • Has an active bacterial, viral, or fungal infection
  • Has active plasma cell leukemia
  • Has extramedullary plasmacytoma(s)
  • Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
  • Has left ventricular ejection fraction (LVEF) < 40%
  • Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission
  • Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study

Additional Trial Information

Phase 1

Enrollment: 54 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of California Davis Comprehensive Cancer Center

Sacramento, CA

Not Yet Accepting


University of Oklahoma Health Sciences Center

Oklahoma City, OK

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message